You are here

Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

EP Vantage

Tue, 03/21/23 - 09:54 am

Tags:

AAD, hidradenitis suppurativa, AbbVie, Humira, UCB Pharma, Bimzelx, Acelyrin, izokibep

AbbVie’s Skyrizi hits the spot in refractory psoriasis

Pharmaphorum

Mon, 03/20/23 - 11:21 am

Tags:

AbbVie, Skyrizi, psoriasis

AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate

Fierce Pharma

Wed, 03/15/23 - 11:25 am

Tags:

Pfizer, AbbVie, Humira, drug pricing, inflation

AbbVie braces for 'greater erosion' of Humira franchise in second half of this year

Endpoints

Tue, 03/7/23 - 10:22 pm

Tags:

AbbVie, Humira, Rinvoq

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff

Fierce Pharma

Tue, 03/7/23 - 11:55 am

Tags:

AbbVie, Pharma CEOs, executive pay, Humira, Richard Gonzalez

AbbVie and Capsida Biotherapeutics partner on eye disease focused gene therapies

Biopharma Reporter

Mon, 02/27/23 - 09:59 am

Tags:

AbbVie, Capsida Biotherapeutics, eye disease, drug development

AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases

BioSpace

Thu, 02/23/23 - 10:02 am

Tags:

AbbVie, Capsida Biotherapeutics, gene therapy, eye disease

Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’

BioPharma Dive

Tue, 02/21/23 - 11:05 am

Tags:

Big Pharma, patents, patent cliff, biosimilars, AbbVie, Humira, Merck, Keytruda, Bristol Myers Squibb, Opdivo

Years after the first US biosim launches, doctors still have their concerns: survey

Fierce Pharma

Thu, 02/16/23 - 04:49 pm

Tags:

biosimilars, PBMs, physicians, AbbVie, Humira, Amgen, Amjevita

The world needs Garp, according to Abbvie

EP Vantage

Fri, 02/10/23 - 10:20 am

Tags:

AbbVie, GARP, Argenx, R&D

AbbVie talks next steps as first Humira competitor makes it to market

Endpoints

Thu, 02/9/23 - 06:01 pm

Tags:

AbbVie, Humira, biosimilars, Rick Gonzalez

AbbVie opens up to bigger deals as competition heats up

Endpoints

Mon, 02/6/23 - 06:19 pm

Tags:

After AbbVie, Teva walks away from influential trade group PhRMA

Fierce Pharma

Mon, 02/6/23 - 10:32 am

Tags:

Teva Pharmaceutical, PhRMA, AbbVie, lobbying

Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita

Forbes

Wed, 02/1/23 - 10:41 am

Tags:

Amgen, Amjevita, AbbVie, Humira, biosimilars, drug pricing

Amgen launches Humira biosimilar, releases Q4 earnings report

Medical Marketing and Media

Tue, 01/31/23 - 11:21 pm

Tags:

Amgen, Humira, biosimilars, earnings, AbbVie, Amjevita

Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug

BioPharma Dive

Tue, 01/31/23 - 12:37 pm

Tags:

AbbVie, Humira, biosimilars, Amgen

The end of the Humira era

EP Vantage

Mon, 01/30/23 - 10:46 am

Tags:

AbbVie, Humira, patents, biosimilars, Merck, Keytruda

Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate

Xtalks

Sun, 01/29/23 - 01:31 pm

Tags:

television ads, pharma marketing, DTC ads, AbbVie, Rinvoq, Dupixent, Sanofi, Regeneron, Skyrizi, Novo Nordisk, Ozempic, Jardiance, Eli Lilly, Boehringer Ingelheim, Rybelsus, Trulicity, Rexulti, Otsuka, Lundbeck, Tremfya, JNJ, Verzenio

AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.

Motley Fool

Sun, 01/22/23 - 01:01 pm

Tags:

AbbVie, Humira, biosimilars

AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out

Fierce Pharma

Wed, 01/18/23 - 10:53 pm

Tags:

AbbVie, Novartis, China, drug pricing, Pfizer, Paxlovid

Pages

last 30 twitter posts